For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240816:nRSP6644Aa&default-theme=true
RNS Number : 6644A Eco Animal Health Group PLC 16 August 2024
16 August 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Posting of the Annual Report and Notice of AGM
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that its Annual Report and Accounts
for the year ended 31 March 2024 and Notice of Annual General Meeting ("AGM")
together with Form of Proxy have today been sent to shareholders who have
elected to receive hard copies by post.
The Annual Report and Accounts is available on the Company's website at
https://ecoanimalhealth.com/investors/
(https://ecoanimalhealth.com/investors/) .
The Company will hold its AGM at The Grange, 100 High Street, London, N14 6BN
on Thursday, 26 September 2024 at 9:00 am.
A copy of the Notice of AGM and Form of Proxy will be available on the
Company's website at https://ecoanimalhealth.com/investors/
(https://ecoanimalhealth.com/investors/) .
-Ends-
For further information please contact:
ECO Animal Health Group plc 020 8447 8899
David Hallas (CEO)
Christopher Wilks (CFO)
Singer Capital Markets (Nominated Adviser & Joint Broker) 020 7496 3000
Phil Davies
Sam Butcher
Investec (Joint Broker) 020 7597 5970
Gary Clarence
Lydia Zychowska
Equity Development 020 7065 2692
Hannah Crowe
Matt Evans
ICR Consilium (Financial PR) 020 3709 5700
Mary-Jane Elliott ecoanimalhealth@consilium-comms.com
Jessica Hodgson
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.
Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ACSMZGMRVKVGDZM